{rfName}
In

Indexed in

License and use

Citations

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Porta, RAuthorCarcereny, EAuthorCardenal, FAuthorRosell, RAuthor

Share

April 6, 2015
Publications
>
Meeting Abstract
No

Initial detection of the double epidermal growth factor receptor (EGFR) mutation (L858R or deletion in exon 19 [del 19] plus T790M) in non-small cell lung cancer (NSCLC) patients (p) with brain metastases (mets) and the influence of first-line chemotherapy on outcome to erlotinib.

Publicated to:Journal Of Clinical Oncology. 29 (15): 7590-7590 - 2011-05-20 29(15), DOI: 10.1200/jco.2011.29.15_suppl.7590

Authors: Moran, T.; Sanchez, J. J.; Molina, M. A.; Bertran-Alamillo, J.; Capitan, A. Gimenez; Benlloch, S.; Taron, M.; Massuti, B.; Camps, C.; Porta, R.; Isla, D.; Lopez-Vivanco, G.; Bover, I.; Garcia-Campelo, M. R.; Rolfo, C. D.; Salazar, F.; Carcereny, E.; Cardenal, F.; Magri, I.; Rosell, R.;

Affiliations

Alicante Univ Hosp, Alicante, Spain - Author
Bellvitge Hosp, Catalan Inst Oncol, Barcelona, Spain - Author
Catalan Inst Oncol, Barcelona, Spain - Author
Clin Rotger, Oncol Unit, Palma De Mallorca, Spain - Author
Complexo Hosp A Coruna, La Coruna, Spain - Author
Consorcio Hosp Gen Univ Valencia, Valencia, Spain - Author
Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Barcelona, Spain - Author
Hosp Cruces, Dept Med Oncol, Baracaldo, Spain - Author
Hosp Josep Trueta, Catalan Inst Oncol, Girona, Spain - Author
Hosp Lozano Blesa, Zaragoza, Spain - Author
Inst Oncol Cordoba, Cordoba, Argentina - Author
Son Llatzer Univ Hosp, Mallorca, Spain - Author
Univ Autonoma Madrid, Madrid, Spain - Author
USP Dexeus Univ Inst, Pangaea Biotech, Barcelona, Spain - Author
See more

Abstract

Keywords

Good health and well-being

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal Of Clinical Oncology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2011, it was in position 5/196, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-08-02:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 3 (PlumX).
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 3 - Good Health and Well-Being, with a probability of 76% according to the mBERT algorithm developed by Aurora University.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: ALEXANDRIA.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (Rosell Costa, Rafael).